Ligand Pharmaceuticals (LGND) Goodwill & Intangibles (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Goodwill & Intangibles data on file, last reported at $318.9 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 11.4% year-over-year to $318.9 million; the trailing twelve-month figure through Mar 2026 stood at $318.9 million (down 11.4% YoY), and the FY2025 full-year result was $327.0 million, down 12.08% from the prior year.
• Goodwill & Intangibles declined to $318.9 million in Q1 2026, from $327.0 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $709.6 million in Q2 2022 to a low of $303.3 million in Q4 2023.
• A 5-year average of $408.0 million and a median of $371.9 million in 2024 frame the typical range for Goodwill & Intangibles.
• Across the five-year window, Goodwill & Intangibles tumbled 39.25% in 2023 and gained 22.61% in 2024, its largest moves.
• Tracing LGND's Goodwill & Intangibles over 5 years: stood at $342.5 million in 2022, then fell by 11.43% to $303.3 million in 2023, then advanced by 22.61% to $371.9 million in 2024, then dropped by 12.08% to $327.0 million in 2025, then retreated by 2.48% to $318.9 million in 2026.
• Business Quant data shows LGND's Goodwill & Intangibles at $318.9 million in Q1 2026, $327.0 million in Q4 2025, and $335.1 million in Q3 2025.